Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on July 23, 2025

MT Newswires

2 days ago

Truist Adjusts Price Target on Gilead Sciences to $108 From $97

MT Newswires

2 days ago

Truist Raises Price Target on Gilead Sciences to $108 From $97, Keeps Hold Rating

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector

Insider Monkey

4 days ago

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

GlobeNewswire

5 days ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

Zacks

5 days ago

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

GlobeNewswire

6 days ago

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player

GlobeNewswire

6 days ago

Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks

6 days ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

MT Newswires

7 days ago

Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

StockStory

7 days ago

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Zacks

8 days ago

Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

MT Newswires

8 days ago

Gilead Sciences Insider Sold Shares Worth $548,700, According to a Recent SEC Filing

MT Newswires

8 days ago

Sector Update: Health Care Stocks Fall Late Afternoon

MT Newswires

8 days ago

Sector Update: Health Care

MT Newswires

8 days ago

Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention

Zacks

8 days ago

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention

Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock

Insider Monkey

8 days ago

Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations

Insider Monkey

8 days ago

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations

MT Newswires

9 days ago

Gilead Says Yeztugo Shows Broad Effectiveness, Tolerability for Diverse HIV Prevention

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

9 days ago

WHO endorses Gilead’s Yeztugo for HIV prevention

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

Business Wire

9 days ago

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

Barrons.com

9 days ago

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom

MT Newswires

12 days ago

Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom

MT Newswires

12 days ago

Equity Markets Close Lower as Trade Tensions Escalate

MT Newswires

12 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

12 days ago

Equity Markets Lower After US Treasury Budget Surplus in June

Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know

StockStory

12 days ago

Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know

MT Newswires

12 days ago

Sector Update: Health Care

Equity Markets Mostly Fall Intraday as Traders Track Tariff Updates

MT Newswires

12 days ago

Equity Markets Mostly Fall Intraday as Traders Track Tariff Updates

MT Newswires

12 days ago

HSBC Adjusts Price Target on Gilead Sciences to $91 From $93, Maintains Hold Rating

MT Newswires

12 days ago

BriaCell Says Bria-IMT Outperforms Trodelvy in Phase 2 Metastatic Breast Cancer Trial

Gilead Sciences, Inc. (GILD): A Bull Case Theory

Insider Monkey

13 days ago

Gilead Sciences, Inc. (GILD): A Bull Case Theory

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Zacks

13 days ago

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

MT Newswires

13 days ago

Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating

Insider Monkey

13 days ago

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Zacks

14 days ago

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Business Wire

14 days ago

AHF: Gilead’s Greed Costs Latin America HIV Protection

Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug

Simply Wall St.

14 days ago

Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug

Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update

Insider Monkey

14 days ago

Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update

$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information

PR Newswire

14 days ago

$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Zacks

14 days ago

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

MT Newswires

14 days ago

Gilead Sciences Signs Agreement With Global Fund to Fight AIDS to Supply HIV Prevention Drug Lenacapavir

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Business Wire

14 days ago

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Zacks

15 days ago

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Zacks

15 days ago

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

MT Newswires

16 days ago

RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating

Argus Research

20 days ago

Technical Assessment: Bullish in the Intermediate-Term

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

Insider Monkey

20 days ago

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

MT Newswires

21 days ago

Gilead Sciences Insider Sold Shares Worth $1,104,484, According to a Recent SEC Filing

Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth

GlobeNewswire

22 days ago

Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth

MT Newswires

23 days ago

Assembly Biosciences Says First Participant Dosed in Phase 1b Study of HSV Drug ABI-1179

Investing.com

23 days ago

Gilead extends gains after Supreme Court upheld an Obamacare provision

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Insider Monkey

25 days ago

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Zacks

a month ago

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care

Investor's Business Daily

a month ago

Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care

Investing.com

a month ago

Kymera’s partnerships with Sanofi and Gilead drive value

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

a month ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Debut Named to TIME's List of the TIME100 Most Influential Companies 2025

PR Newswire

a month ago

Debut Named to TIME's List of the TIME100 Most Influential Companies 2025

Northwell Health named to TIME100 Most Influential Companies 2025 list

Business Wire

a month ago

Northwell Health named to TIME100 Most Influential Companies 2025 list

Kymera weakness a buying opportunity, says Stifel

TipRanks

a month ago

Kymera weakness a buying opportunity, says Stifel

Morning Movers: General Mills dips following fourth quarter report

TipRanks

a month ago

Morning Movers: General Mills dips following fourth quarter report

Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know

Zacks

a month ago

Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know

Alger Russell Innovation Index Updates for Second Quarter 2025

PR Newswire

a month ago

Alger Russell Innovation Index Updates for Second Quarter 2025

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal

Simply Wall St.

a month ago

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal

FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP

Clinical Trials Arena

a month ago

FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP

MT Newswires

a month ago

Assembly Biosciences Says ABI-4334 Phase 1b Trial Showed 'Strong' Antiviral Activity in Chronic Hepatitis B

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

BioPharma Dive

a month ago

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

GlobeNewswire

a month ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

MT Newswires

a month ago

Gilead Sciences, Kymera Therapeutics to Collaborate on Cancer Program

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Business Wire

a month ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion

ACCESS Newswire

a month ago

Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call

StockStory

a month ago

5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Investor's Business Daily

a month ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

BMO says lenacapavir approval for prevention a ‘major win’ for Gilead

TipRanks

a month ago

BMO says lenacapavir approval for prevention a ‘major win’ for Gilead

MT Newswires

a month ago

Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115

FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

Zacks

a month ago

FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Simply Wall St.

a month ago

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

Zacks

a month ago

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

Gilead Sciences’ Yeztugo receives approval from US FDA for HIV

Pharmaceutical Technology

a month ago

Gilead Sciences’ Yeztugo receives approval from US FDA for HIV

Celltrion opens new UK headquarters in Uxbridge, UK

Business Wire

a month ago

Celltrion opens new UK headquarters in Uxbridge, UK

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

Insider Monkey

a month ago

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Insider Monkey

a month ago

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks

a month ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

MT Newswires

a month ago

Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says

Citi sees Gilead clinical holds as only ‘minor setback’

TipRanks

a month ago

Citi sees Gilead clinical holds as only ‘minor setback’

Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital

TipRanks

a month ago

Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720

TipRanks

a month ago

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720

FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down

Zacks

a month ago

FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

Zacks

a month ago

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

Argus Research

a month ago

Technical Assessment: Bullish in the Intermediate-Term

MT Newswires

a month ago

RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating

1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar

StockStory

a month ago

1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar

Why Gilead Scinces Stock Tumbled on Tuesday

Motley Fool

a month ago

Why Gilead Scinces Stock Tumbled on Tuesday

MT Newswires

a month ago

Gilead Says FDA Puts Clinical Hold on HIV Combination Trials

Investing.com

a month ago

Gilead Sciences shares hit after HIV studies placed on hold by FDA

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

2 Reasons to Like GILD (and 1 Not So Much)

StockStory

2 months ago

2 Reasons to Like GILD (and 1 Not So Much)

Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"

ACCESS Newswire

2 months ago

Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"

A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech

The Wall Street Journal

2 months ago

A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech

Share on Social Networks: